VIA EDGAR
December 4, 2020
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attn: Alan Campbell
Re: | Odonate Therapeutics, Inc. |
Registration Statement on Form S-3
Filed November 27, 2020
File No. 333-250993
Dear Mr. Campbell:
Odonate Therapeutics, Inc., a Delaware corporation (the “Company”), respectfully requests pursuant to Rule 461 under the Securities Act of 1933, as amended, that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-250993) be accelerated and that it be declared effective on December 8, 2020 at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
|
|
| Sincerely,
|
|
|
|
| /s/ Michael Hearne |
|
|
|
| Michael Hearne |
|
|
|
| Chief Financial Officer |
|
cc: | Ryan Murr, Gibson, Dunn & Crutcher LLP |